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Several recent studies describe the influence of the
gut microbiota on host brain and behavior. However,
the mechanisms responsible for microbiota-nervous
system interactions are largely unknown. Using a
combination of genetics, biochemistry, and crystal-
lography, we identify and characterize two phyloge-
netically distinct enzymes found in the human micro-
biome that decarboxylate tryptophan to form the
b-arylamine neurotransmitter tryptamine. Although
this enzymatic activity is exceedingly rare among
bacteria more broadly, analysis of the Human Micro-
biome Project data demonstrate that at least 10% of
the human population harbors at least one bacterium
encoding a tryptophan decarboxylase in their gut
community. Our results uncover a previously unrec-
ognized enzymatic activity that can give rise to
host-modulatory compounds and suggests a poten-
tial direct mechanism by which gut microbiota can
influence host physiology, including behavior.
INTRODUCTION
It is becoming increasingly clear that the gut microbiota are
important for nervous system function. In 1978, excessive levels
of the intestinal hormone VIP (vasoactive intestinal peptide) were
discovered in cerebrospinal fluid (Ebeid et al., 1978), establishing
a connection between the gut and the brain. Over the past three
decades, this relationship has expanded to include pathways in
the autonomic and enteric nervous systems, the neuroendocrine
system, and the immune system. More recently, the ability of the
intestinal microbiota to modulate host neurological activity has
become a focus of investigation. A 2004 study comparing
germ-free and specific-pathogen-free mice demonstrated that
the microbiota are required for the development of the hypotha-
lamic-pituitary-adrenal (HPA) system, which is important for host
stress response (Sudo et al., 2004). Additional studies showedCell Hosthat the vagus nerve is a major communication pathway used
by gut bacteria to influence neurochemistry and behavior (Bravo
et al., 2011) and established a role for gut microbial colonization
in modulating neuronal circuits involved in motor control and
anxiety behavior (Diaz Heijtz et al., 2011). A recent paper from
Mazmanian and coworkers used thematernal immune activation
model of autism spectrum disorder to demonstrate a role for the
microbiota in the development of autism and implicated amicro-
biota-derived metabolite, 4-ethylphenylsulfate, in its pathology
(Hsiao et al., 2013). While it is now firmly established that the
gut microbiota influence brain and behavior, the molecular
mechanisms responsible for these phenomena have only begun
to be explored.
In the work reported here, we had originally intended to char-
acterize a pathway for the reductive metabolism of aromatic
amino acids by the common gut Firmicute Clostridium sporo-
genes. In the course of carrying out preliminary experiments,
we made the unexpected observation that C. sporogenes
ATCC 15579 is capable of decarboxylating tryptophan (Trp) to
tryptamine (Figure 1A), an activity that is exceedingly rare among
bacteria. Here, we report the discovery and characterization of
the C. sporogenes Trp decarboxylase, along with a phylogeny-
informed screen of additional decarboxylases from the gut mi-
crobiota that led us to a second, unrelated Trp decarboxylase
from another gut Firmicute, Ruminococcus gnavus. We then
explore the structural determinants of Trp selectivity in the
R. gnavus decarboxylase and show that at least 10% of the hu-
man population harbors one of these enzymes, opening the door
to future efforts to explore their potential role in mediating a
microbe-host interaction.
RESULTS
Clostridium sporogenes Decarboxylates Tryptophan
to Tryptamine
We began with an interest in the reductive metabolism of aro-
matic amino acids by gut-associated species of Clostridium. In
an effort to characterize the primary products to which trypto-
phan (Trp) was converted, we cultivated the common gut Firmi-
cute Clostridium sporogenes ATCC 15579 in rich medium and
then transferred the cell material into minimal medium to whicht & Microbe 16, 495–503, October 8, 2014 ª2014 Elsevier Inc. 495
TAM TRP ILA IPA
A
B
24 h
0 h
0 5 10 15 20 25 30 35 40
N
H
NH2
OH
O
N
H
NH2
tryptaminetryptophan
CO2
Clostridium sporogenes
Figure 1. Tryptamine Production by C. sporogenes
(A) The proteinogenic amino acid L-tryptophan is decarboxylated to trypt-
amine, a biogenic amine neurotransmitter, by the action of pyridoxal phos-
phate (PLP)-dependent decarboxylases.
(B) Whole C. sporogenes were grown anaerobically in minimal media con-
taining 5 g/L tryptophan and clarified supernatant was analyzed by HPLC.
C. sporogenes converts tryptophan (12.5 min) into tryptamine (TAM, 10.5 min),
indole lactic acid (ILA, 22min), and indole propionic acid (IPA, 28min). See also
Figures S1 and S5.
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Figure 2. CLOSPO_02083 and RUMGNA_01526 Are Trp Decarboxy-
lases
(A) Purified CLOSPO_02083 (100 nM) was incubated with 2.5 mM tryptophan
for 10 min and quenched with 1 volume MeOH; 100 ml of the reaction mixture
was analyzed by HPLC. The HPLC trace shows the conversion of tryptophan
(TRP, 9 min) to tryptamine (TAM, 7 min).
(B) R. gnavus was grown anaerobically in minimal media containing 5 g/L
tryptophan; 100 ml of the clarified supernatant was analyzed by HPLC. The
HPLC trace shows the conversion of tryptophan (TRP, 12.5 min) to tryptamine
(TAM, 10.9 min). Note: Different HPLC methods were used for (A) and (B).
(C and D) Rate (mM tryptamine/min) versus substrate concentration curves for
tryptophan decarboxylation by (C) CLOSPO_02083 or (D) RUMGNA_01526.
Enzyme was incubated with concentrations of tryptophan that varied from
0.15–24.5 mM. Error represents standard error of the mean. GraphPad was
used to fit the Michaelis-Menten curve. See also Figure S2. Kinetic values are
summarized in Figure S3.
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Tryptamine Production in the Human MicrobiomeTrp had been added. In extracts of these cultures, reverse-phase
HPLC-MS analysis revealed an unexpected conversion product
that was distinct from the known products of reductive Trpmeta-
bolism, indole lactic acid and indole propionic acid (Figure 1B).
Since the mass of the unknown peak corresponded to the loss
of the carboxylic acid group from Trp ([M+H]+ m/z: calculated
161.22, observed 161.12), we tested and confirmed the identity
of this compound to be tryptamine by coinjection with an
authentic standard and by comparison of its 1H NMR spectrum
to that of an authentic standard (Figure S1A). Notably, the pres-
ence of tryptamine in the culture fluid ofC. sporogenes indicated
that tryptamine was not only being produced but also excreted
from the cytoplasm to the extracellular space.
Identification of CLOSPO_02083 as a Trp Decarboxylase
We next set out to identify the enzyme responsible for Trp decar-
boxylation inC. sporogenes ATCC 15579. The two enzyme clas-
sesmost commonly associatedwith amino acid decarboxylation
are the pyridoxal 50-phosphate (PLP)-dependent decarboxy-
lases, in which the catalytic cycle begins with the covalent link-
age of the substrate a-amine to PLP as a Schiff base (John,
1995; Schneider et al., 2000), and the pyruvoyl-dependent de-
carboxylases, in which a covalently bound pyruvoyl cofactor
arises from an autocatalytic posttranslational modification (Gal-
lagher et al., 1993; van Poelje and Snell, 1990). A computational
search of the C. sporogenes ATCC 15579 genome sequence re-
vealed three putative PLP-dependent decarboxylases, but no
putative pyruvoyl-dependent enzymes.496 Cell Host & Microbe 16, 495–503, October 8, 2014 ª2014 ElsevieNone of the three genes were annotated as Trp decarboxy-
lases; CLOSPO_02083 was predicted to be a tyrosine (Tyr)
decarboxylase, while CLOSPO_03076 and CLOSPO_00504
were predicted to be glutamate decarboxylases. We began by
characterizing CLOSPO_02083, hypothesizing that its annota-
tion might be correct and Trp decarboxylation was a secondary
activity—or incorrect but close, since Tyr and Trp are both
aromatic amino acids. The CLOSPO_02083 gene was amplified
by PCR from C. sporogenes genomic DNA, subcloned into
the pET-28a expression vector, and heterologously overex-
pressed in E. coli BL21 (DE3) as an N-terminal His6 fusion pro-
tein. CLOSPO_02083 fusion protein was purified by immobilized
nickel affinity chromatography to > 95% homogeneity (Fig-
ure S1B). When CLOSPO_02083 was incubated with Trp for
6 min at 37C, HPLC analysis of the reaction mixture revealed
a new peak (Figure 2A). The identity of the corresponding com-
pound was consistent with tryptamine by coelution with an
authentic standard.
Kinetic Analysis of CLOSPO_02083 Activity with
Aromatic Amino Acid Substrates
The previous result shows that CLOSPO_02083 is capable of de-
carboxylating Trp, but it does not rule out the possibility that oner Inc.
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To gain insight into the substrate selectivity of CLOSPO_02083,
we measured the basic kinetic parameters for CLOSPO_02083-
catalyzed decarboxylation of the aromatic amino acids Trp,
Tyr, and phenylalanine (Phe). To determine kcat and Km for
CLOSPO_02083, the concentration of the amino acid sub-
strate was varied under initial velocity conditions (Figures
2C and S4A). Trp is a robust substrate for decarboxylation
CLOSPO_02083 with a Km of 2.8 ± 0.0 mM, kcat of 1200 min
1
and kcat/Km of 7.3 3 10
3 M1sec1. The activity of
CLOSPO_02083 against Phe was undetectable up to 90 mM
substrate (Figure S1C). Although the limited solubility of Tyr
prevented us from obtaining kinetic parameters, at the highest
concentration of Tyr we tested, CLOSPO_02083 was 600-fold
more efficient at decarboxylating Trp (Figure S1D). Collectively,
these results show that Trp is accepted more efficiently as a
substrate than Phe or Tyr.
These results suggest that the database annotation of
CLOSPO_02083 as a Tyr decarboxylase is incorrect. The
chemical distinction between Tyr and Trp is mild, since they
are both aromatic amino acids. However, the biological
distinction between their decarboxylation products is sharp:
tyramine stimulates a pressor response that results in an in-
crease in blood pressure (Bianchetti et al., 1982), whereas
tryptamine induces the release of serotonin from enterochro-
maffin cells and stimulates GI motility (Takaki et al., 1985).
Thus, a modest difference in a decarboxylase’s substrate
selectivity can lead to entirely distinct biological outcomes,
placing a premium on biochemically characterizing the sub-
strate selectivity of amino acid decarboxylases expressed
by gut commensals.
A Phylogenetic Analysis of Bacterial Decarboxylases to
Select a Functionally Diverse Set of 15 Candidate
Enzymes
Several other gut-associated Clostridium spp. harbor a homolog
of CLOSPO_02083, but this enzyme does not appear to be pre-
sent in other gut Firmicutes. We next asked whether there exist
additional unrelated Trp decarboxylases among the human mi-
crobiota. The only putative tryptophan decarboxylases in the
NCBI databases come from plant and fungal genomes, but the
fact that CLOSPO_02083 was misannotated as a Tyr decarbox-
ylase led us to hypothesize that there might be other mis- or un-
annotated decarboxylases encoded by the microbiota that are
Trp selective.
To select a small panel of candidate decarboxylases from the
microbiota, we performed a phylogenetic analysis of bacterial
decarboxylases in which protein sequences were grouped into
clades in which members are predicted to share a similar (if
not identical) substrate selectivity. We then chose 15 enzymes
for characterization in a manner that maximized our ability to
search the functional space of microbiome decarboxylases: at
least one sequence from each of the largest clades and three
additional sequences from smaller clades (Figure S2A). We ob-
tained and cultivated each of the host organisms to isolate
genomic DNA. The candidate decarboxylases were amplified
by PCR, subcloned into the pET-28a expression vector, and het-
erologously overexpressed in E. coli BL21 as N-terminal His6
fusion proteins.Cell HosA Phylogeny-Informed Screen for Additional Trp
Decarboxylases from the Microbiota
Since our aim was to discover Trp decarboxylases rather than to
obtain kinetic parameters for each enzyme in our screening
panel, we developed and employed a whole-cell assay to rapidly
assess the substrate selectivity of our candidate decarboxy-
lases. E. coli BL21 (DE3) harboring candidate decarboxylases
in pET-28a expression vectors were cultivated in rich medium
and grown to stationary phase. The cells were transferred into
minimal medium containing an aromatic amino acid substrate
(Trp, Tyr, or Phe), and decarboxylation was monitored by
analyzing cell-free culture fluid by analytical HPLC. This assay
takes advantage of the fact that b-arylamines, the products of
decarboxylase activity in the E. coli cytoplasm, could easily be
detected in the extracellular fluid of E. coli cultures we screened
and are not produced by wild-type E. coli.
An important limitation of the assay is that it is qualitative; in a
manner that is likely due to differences in the level of active
enzyme expressed, a more robust activity in the cell-based
assay did not always translate into an enzymewith more efficient
kinetic parameters. Moreover, we find that the assay detects
low-level activities that may not be physiologically relevant, so
a positive result only indicates the possibility of an activity and
must be confirmed biochemically.
Nevertheless,ourqualitativeassayenabledus to rapidly screen
15 decarboxylases against three substrates (Figure S2B). One of
the enzymes we screened, RUMGNA_01526, appeared to be
capable of decarboxylating Trp robustly; notably, this enzyme
was only very distantly related to CLOSPO_02083 (26% amino
acid sequence identity). To confirm this result biochemically, we
purified RUMGNA_01526 fusion protein by immobilized nickel
affinity chromatography to >95% homogeneity (Figure S1B).
RUMGNA_01526 Is a Trp Decarboxylase
We measured the basic kinetic parameters for the decarboxyl-
ation of Trp, Tyr, and Phe by RUMGNA_01526. As shown in
Figure 2D, Trp is a robust substrate for decarboxylation, with
a kcat of 4400 min
1, a Km of 1.1 ± 0.1 mM, and a kcat/Km
of 6.8 3 104 M1sec1. In spite of the robust activity of
RUMGNA_01526 against Trp, Tyr, and Phe in the cell-based
assay, the catalytic efficiency of RUMGNA_01526 for Trp is
>1000-fold higher than it is for Phe (Figures 2D and S4B), due
to the combination of a higher kcat (19-fold) and a lower Km
(70-fold). Although the limited solubility of Tyr prevented us
from obtaining kinetic parameters, at the highest concentration
of Tyr we tested, RUMGNA_01526 was 1000-fold more efficient
at decarboxylating Trp. These data suggest that tryptophan is
the native substrate of RUMGNA_01526 (Figures S1C and S1D).
R. gnavus Excretes Tryptamine into the Extracellular
Fluid
We showed above (Figure 1B) that C. sporogenes excretes the
tryptamine generated by CLOSPO_02083 into the culture fluid.
However, tryptamine produced in the cytoplasmcould have a va-
riety of alternative intracellular fates, including serving as a build-
ingblock for the synthesisof a largermolecule.Havingshown that
RUMGNA_01526 is a Trp decarboxylase, we next askedwhether
R. gnavus excretes the tryptamine fromRUMGNA_01526 into the
extracellular space. We cultivated R. gnavus in rich medium untilt & Microbe 16, 495–503, October 8, 2014 ª2014 Elsevier Inc. 497
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Figure 3. Crystal Structure of Apo and
Ligand-bound RUMGNA_01526
(A) Schematic of proposed inhibitor mechanism:
(S)-a-FMT (I) is converted to a PLP-(S)-a-FMT
external aldimine intermediate (II), which un-
dergoes decarboxylation, fluoride ion elimination,
and transaldimination to form a PLP-(S)-alpha-
FMT ketone adduct (III).
(B) Overlay of ligand-free (monomer A, light
gray; monomer B, dark gray) and ligand-bound
(monomer A, cyan; monomer B, blue) structures.
In the active and allosteric sites, PLP-(S)-
a-FMT and (S)-a-FMT (respectively) are shown in
spheres.
(C) Active site with PLP-(S)-a-FMT bound reveals
a repositioning of Tyr335 and Phe98. In the ligand-
bound structure, Lys306 is no longer covalently
bound to PLP.
(D) Upon engagement of (S)-a-FMT, residues 337–
349 (dark blue spheres) fold over the active site,
excluding solvent and forming critical interactions
with the inhibitor. Dark gray spheres represent
only ordered residues in apo structure. See also
Figures S4 and S6.
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dium in the absence or presence of addedTrp, andmonitored the
extracellular fluid by analytical HPLC. We observed that after
72 hr, the concentration of tryptamine reached 1.7 mM (Fig-
ure 2B), showing that R. gnavus excretes tryptamine in vitro and
suggesting that this strain has the potential to excrete tryptamine
in the ecological setting of the gut lumen.
Tryptamine Induces Ion Secretion by Intestinal
Epithelial Cells
The function of tryptamine in the context of microbe-host
signaling in the gut is not well understood. As a starting point
for exploring the physiology of tryptamine-mediated signaling,
we performed an experiment to test whether tryptamine is
capable of inducing ion secretion by intestinal epithelial cells.
Using an Ussing chamber, a segment of proximal-mid murine
colon mucosa was exposed to two concentrations of tryptamine
and the change of short circuit current wasmeasured. At 3mM, a
concentration comparable to the active concentration of other
bacterial fermentation products such as short-chain fatty acids,
tryptamine induced a significant change in short circuit current,
confirming that it can affect colonic ion secretion (Figure S5).
Since colonic ion secretion plays an important role in gastroin-
testinal motility, this result suggests that tryptamine-mediated
signaling might affect the transit of food particles and bacterial
cells through the gut lumen.
RUMGNA_01526 Is a Fold Type I PLP-Dependent
Decarboxylase
We decided to use a combination of structural biology and phy-
logenetics to better understand the provenance of bacterial Trp
decarboxylases. Crystals of CLOSPO_02083 in the apo form
failed to diffract to an adequate resolution, but we determined498 Cell Host & Microbe 16, 495–503, October 8, 2014 ª2014 Elseviethe crystal structure of RUMGNA_01526 at 2.8 A˚. The enzyme
forms a dimer with 4565 A˚2 buried at the dimer interface. The
active site is located at the dimer interface and therefore the
enzyme is only functional in the dimeric state. The monomeric
unit is comprised of three domains: an N-terminal domain con-
taining three parallel a helices that pack against the other
monomer, a large domain comprised of a nine-stranded b sheet
surrounded by nine a helices containing the PLP-binding site,
and a smaller C-terminal domain comprised of a four-strand
anti-parallel b sheet surrounded by three a helices (Figure 3B).
The structure is nearly identical to the open form of human gluta-
mate decarboxylase (GAD65), with an overall a-carbon RMSD of
1.07A˚ (Fenalti et al., 2007). Similar comparisons can be made to
human aromatic amino acid decarboxylase (Giardina et al.,
2011) and wild boar DOPA decarboxylase (Burkhard et al.,
2001), with a-carbon RMSDs of 1.21A˚ and 1.23A˚, respectively.
The agreement between these structures highlights the com-
monality of this enzymatic fold, even across multiple species.
(S)-a-Fluoromethyltryptophan Is an Inhibitor of
RUMGNA_01526
The close structural relationship between RUMGNA_01526
and glutamate decarboxylase raises the question of how the
structural scaffold of RUMGNA_01526 accommodates the
large, hydrophobic substrate Trp. Since the ideal approach to
answering this question would involve determining the structure
of RUMGNA_01526 bound to a Trp-mimicking inhibitor, we
proceeded to determine whether a previously reported inhibitor
of plant Trp decarboxylase, (S)-a-fluoromethyltryptophan ([S]-
a-FMT; Figure 3A, I), was an inhibitor of RUMGNA_01526
(Ishihara et al., 2011).
Although mechanistic studies have not been performed
to determine the mode of Trp decarboxylase inhibition byr Inc.
A B
DC
Figure 4. Decarboxylase Inhibition by (S)-
a-FMT
Progress curve of tryptamine production by (A)
CLOSPO_02083 and (B) RUMGNA_01526 in the
presence of (A) 10 mM or (B) 2.5 mM tryptophan at
various concentrations of inhibitor. Data were fit to
the equation described in Supplemental Experi-
mental Procedures to obtain kobs.
(C and D) Plot of kobs versus [I]. CLOPSO_02083
is inhibited more potently by (S)-a-FMT than
RUMGNA_01526 due to a higher binding affinity of
the inhibitor. Error represents standard error of the
mean. See also Figure S3.
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(S)-a-fluoromethylhistidine ([S]-a-FMH), show that this inhibitor
blocks histidine decarboxylase in a mechanism-dependent
fashion that involves the formation of a covalent adduct between
the inhibitor and PLP.
We measured the production of tryptamine by HPLC in the
presence of various concentrations of inhibitor over 30 min and
analyzed progress curves of the reaction to assess the kinetics
of inhibition. Indeed, not only for RUMGNA_01526 but also
for CLOSPO_02083, we observed progress curves in the
presence of increasing concentrations of inhibitor, consistent
with covalent inhibition (Figures 4A and 4B). Despite having a
comparable Km for Trp, RUMGNA_01526 has a weaker affinity
for (S)-a-FMT than CLOSPO_02083 (Ki of 178 mM versus
0.2 mM). However, it is more rapidly inhibited (kinact of 1.2 min
1
versus 0.1 min1), suggesting that once the weak enzyme-inhib-
itor complex forms, the relative orientation of PLP and the inhib-
itor is conducive to covalent bond formation (Figures 4C and 4D).
The inactivation of histidine decarboxylase by (S)-a-FMH is
initiated by substrate decarboxylation followed by the elimina-
tion of fluoride ion (Bhattacharjee and Snell, 1990; Hayashi
et al., 1986). A transaldimination releases the enamine, which
can react and inactivate the PLP cofactor. In order to elucidate
the mechanism by which (S)-a-FMT inhibits RUMGNA_01526,
as well as to understand how RUMGNA_01526 accommodates
the large, hydrophobic substrate Trp, we sought to determine
the X-ray crystal structure of the inhibitor-bound enzyme.
A Key Loop Gates the Active Site and Contacts the
Indole Side Chain of the Substrate Trp
We determined the crystal structure of inhibitor-bound
RUMGNA_01526 at 2.8 A˚. In the active site of the native enzyme,
which is located in a cleft at the dimer interface, continuous elec-
tron density shows PLP covalently linked to K306 through a
Schiff base. The major difference between the native and (S)-
a-FMT-bound structures is the conformation of an extended
loop (residues 337–349). The homologous loop was previouslyCell Host & Microbe 16, 495–503identified as a major difference between
GAD65 and GAD67, where differences
in conformational dynamics are thought
to be responsible for auto-inactivation
of GAD65 (Fenalti et al., 2007). In porcine
DOPA decarboxylase, this loop was
disordered in three data sets from
complexes with different inhibitors,complicating structure-based drug design and an assessment
of catalytic mechanisms (Burkhard et al., 2001). In contrast, we
observed that when bound to PLP alone, this loop was partially
disordered and the remaining ordered components jutted
away from the active site, leaving the active site solvent-
exposed. Upon engagement of (S)-a-FMT, electron density
became clearer and the loop folded over the active site,
excluding solvent and forming critical interactions with the inhib-
itor (Figure 3D). These data are consistent with a model in which
loop 337–349 gates the active site, adopting a partially disor-
dered, outward-facing conformation in the absence of substrate
that enables access to the active site, and closing down to cap
the active site after substrate entry.
Two other flexible loops within the active site of the inhibitor-
bound enzyme are reordered to accommodate the indole side
chain of (S)-a-FMT. In the absence of substrate, the first loop
(residues 95–101) leaves the active site accessible for the entry
of a substrate with a large aromatic side chain. Upon substrate
binding, the loop conformational change places the phenyl ring
of Phe98 directly above the p-system of the indole ring, stabiliz-
ing the inhibitor through ap-stacking interaction (Figure 3C). This
loop appears to be a critical element for defining substrate selec-
tivity; consistent with this possibility, it is conserved among de-
carboxylases in several related Firmicutes (discussed below).
The second loop, residues 329–336, reorients to shift the
phenolic side chain of Tyr335 closer to the active site, increasing
the hydrophobicity of the substrate-binding pocket.
Insights into the Mechanism of Inhibition by (S)-a-FMT
and a Potential Allosteric Site
In the inhibitor-bound structure, (S)-a-FMT has been decarboxy-
lated; however, it has not been defluorinated as seen in the
mechanism of (S)-a-FMH inhibition of histidine decarboxylase
and remains covalently linked to PLP. This is supported by the
absence of a suitable nucleophile in the active site that could
be covalently modified by the defluorinated (S)-a-FMT-PLP
adduct., October 8, 2014 ª2014 Elsevier Inc. 499
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Figure 5. Sequence and Structural Analysis of Aromatic Amino Acid Decarboxylases
(A) The dendrogram on the left shows the degree of sequence similarity between various decarboxylases.
(B) Alignment of select amino acid decarboxylases are numbered according to the RUMGNA_01526 sequence. Four structural components of RUMGNA_01526
important for substrate binding are highlighted. The bars above consensus sequence show the degree of sequence conservation; residues from the
RUMGNA_01526 structure that interact (black bars) or do not interact (white) with the tryptophan substrate are indicated. Residues in the sequence alignment are
colored according to the Clustal color code (http://ekhidna.biocenter.helsinki.fi/pfam2/clustal_colours).
(C) RUMGNA_10526 active site showing residues represented by black bars in (B).
Cell Host & Microbe
Tryptamine Production in the Human MicrobiomeThe (S)-a-FMT-PLP adduct (Figure 3A, III) is relatively disor-
dered in the electron density maps of both active sites; however,
the maps show an absence of density consistent with a covalent
linkage between PLP and the enzyme. To further probe the iden-
tity of the adduct, we denatured the enzyme after incubation with
PLP and (S)-a-FMT and analyzed the released product (Fig-
ure S10). We found a single species of mass 403, which most
likely represents the ketone formed after (S)-a-FMT is decar-
boxylated, defluorinated, and deaminated (Figure S10, IV). The
same adduct is also found during the inactivation of histidine de-
carboxylase by (S)-a-fluoromethylhistidine (Bhattacharjee and
Snell, 1990). Collectively, these data indicate that the PLP-(S)-
a-FMT adduct is formed and remains tightly bound rather
than diffusing out of the active site. Thus, the blockade of
RUMGNA_01526 by (S)-a-FMT appears to be an enzyme-cata-
lyzed inactivation of the PLP coenzyme and does not involve a
chemical modification of the enzyme itself.
Surprisingly, we observed an additional molecule of (S)-a-FMT
bound to a site20 A˚ from the active site (Figure S4C). The inhib-
itor fits inside a hydrophobic pocket that is formed by the move-
ment of an N-terminal loop (residues 16–22) and makes
hydrogen bonds to S105 and the backbone of P102. While this
binding event might be a crystallization artifact, the kinetic data
are consistent with the possibility of cooperative substrate bind-
ing to an allosteric site as evidenced by a slight increase in the r2
value for the fit to the Hill equation (Hill coefficient = 1.87) versus
the Michaelis-Menten equation (Figures S3, S4A, and S4B).
Evolutionary Insights from Sequence and Structure into
the Substrate Selectivity and Origins of Bacterial Trp
Decarboxylases
To better understand the mechanisms underlying the substrate
recognition and specificity, we next aligned the amino acid se-500 Cell Host & Microbe 16, 495–503, October 8, 2014 ª2014 Elseviequences of 21 enzymes: 15 decarboxylases from the phylog-
eny-informed screen, 3 annotated histidine decarboxylases,
and 3 decarboxylases with known structure. Three notable pat-
terns are apparent from the multiple sequence alignment. First,
while the multiple sequence alignment shows a high degree of
similarity between the amino-acid substrate binding sites of
the glutamate decarboxylases, the binding sites that accommo-
date aromatic amino-acid substrates differ significantly (Fig-
ure 5). With the exception of one enzyme (EEB27310), the only
residue shared by all the sequences is K306, the active site lysine
residue involved in binding PLP. Second, no apparent rules were
found in the sequence alignment of the decarboxylases with ar-
omatic amino acids as substrates that could explain their spec-
ificities or promiscuities for the aromatic amino acids; therefore,
it is likely that the aromatic amino acid substrate specificity is
governed by differences in the active site structures and/or ori-
entations of the substrates. Even the serine residue at position
356 (354 in the original sequence) that was found to determine
the histidine specificity of the human histidine decarboxylase
(Komori et al., 2012) is found in other decarboxylases with no
observed histidine activity (data not shown). Third, the binding
sites of decarboxylases with aromatic amino acid substrates
are rich in proline residues, suggesting that the specificity for
different aromatic amino acid substrates could also be driven
by active sites whose shapes match more rigidly those of the
substrates.
Trp Decarboxylases Are Present in At Least 10% of the
Samples from the NIH Human Microbiome Project
Initial assemblies of sequenced human stool samples from 86
healthy subjects were examined for the presence of similar
amino acid decarboxylases. We used BLASTP to search the
metagenomic contigs for homologs of RUMGNA_01526. In total,r Inc.
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Figure 6. Presence of Tryptophan Decarboxylase in the Human Microbiome Project Samples
Accession numbers of proteins of highest sequence identity to RUMGNA_01526 (ZP_02040762). BLAST percent identity was calculated for at least 100 amino
acids. Fifteen subjects were found to contain homologs of the putative tryptophan decarboxylases. Of those, two contained 2 different homologs, and 13
contained one homolog. One subject harbored a gene with 93% identity to either ZP_0204072 from R. gnavus or HMPREF9477_00579 from Lachnospiraceae
bacterium 2_1_58FAA. A sequence alignment is presented highlighting the residues identified by our structural analysis to be important for accommodating
tryptophan (black bars). (a) Lachnospiraceae bacterium 2_1_58FAA, (b) Blautia hansenii DSM 20583, and (c) Desulfitobacterium dehalogenans ATCC 51507.
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Tryptamine Production in the Human Microbiomewe identified homologs of RUMGNA_01526 in 15 subjects
(17% of the samples). Of those, 13 subjects contained only
one decarboxylase homolog, while two subjects harbored
two different homologs. Eight subjects (9.3%) contained a
Trp decarboxylase homolog that is almost identical to the
RUMGNA_01526 characterized here (>99% identical at the
amino acid level over >100 residues). The rest of the samples
harbored decarboxylase homologs that were 62%–93% iden-
tical to RUMGNA_01526 over >100 residues (Figure 6). Although
further biochemical characterization is needed to assign these
more distantly related homologs as aromatic amino acid decar-
boxylases, a sequence alignment to RUMGNA_01526 shows
nearly 100% identity over the residues critical for accepting tryp-
tophan (Figure 6). These homologs were highly similar to genes
from a variety of anaerobic Firmicute reference genomes, such
as Clostridium asparagiforme, Clostridium nexile, Desulfitobac-
terium dehalogenans, and Blautia hansenii. Despite the fact
that C. sporogenes ATCC 15579 is a human gut isolate, similar
searches with CLOSPO_02083 yielded no hits. The presence
of Trp decarboxylase homologs in 9%–17% of gut metage-
nomes of a random population of healthy humans suggests
that tryptamine produced by gut bacteria may bemore prevalent
in humans than previously thought.
DISCUSSION
The production of tryptamine by C. sporogenes was notable for
three reasons. First, while the decarboxylation of tryptophan to
tryptamine is common in the plant kingdom (Facchini et al.,
2000), Trp decarboxylation is an exceedingly rare activity among
bacteria. To our knowledge, the only bacterial species in which
this transformation is known are Xenorhabdus nematophilus
and Bacillus atrophaeus, which are thought to produce trypt-
amine as a building block for the biosynthesis of larger natural
products (Lang et al., 2008; Li et al., 1997; Proschak et al.,
2011; Yuwen et al., 2013), and Lactobacillus bulgaricus, the
only bacterial species known to excrete tryptamine (Chander
et al., 1989).
Second, tryptamine is ab-arylamineneurotransmitter known to
have a range of biological activities. As a trace amine found in low
quantities in the brain, it is a ligand for the trace amine-associated
receptors (TAARs) that potentiates the inhibitory responseof cellsCell Hosto serotonin (Borowsky et al., 2001; Zucchi et al., 2006), aswell as
a ligand for the sigma-2 receptor (Fontanilla et al., 2009). More-
over, tryptamine has been observed in human and rodent feces
(Anderson, 1975; Brooks et al., 1984), where it is known to induce
the release of serotonin by enterochromaffin cells (Takaki et al.,
1985). Fluctuations in intestinal serotonin levels are thought
to modulate GI motility (Lundgren, 1998; Turvill et al., 2000) and
may play a role in the pathology of inflammatory bowel diseases
(Bischoff et al., 2009; Lindenetal., 2003,2005). Thesefindingsare
especially interesting in light of the critical role serotonin plays as
a signaling molecule in the enteric nervous system (Mayer, 2011;
Ormsbee and Fondacaro, 1985), where modulation of the sero-
tonin receptors has been proposed as a treatment for irritable
bowel syndrome (Gershon and Tack, 2007; Mawe et al., 2006).
Indeed, the gut microbiome of IBS patients is often dominated
by Firmicutes (Jeffery et al., 2012), the phylum from which
the decarboxylases described here derive, raising the question
of whether the bacterial production of tryptamine plays a role in
the pathogenesis of IBS.
Third, tryptamine production represents a microbiota-medi-
ated alteration in tryptophan metabolism. Host serotonin is pro-
duced from dietary tryptophan and metabolomic profiling has
shown that germ-free mice have a 2.8-fold decrease in plasma
serotonin over conventionalized mice, and elevated levels
of tryptophan (Wikoff et al., 2009). Additionally, the level of
tryptamine in feces increases by 200% in conventional verus
germ-free mice (Marcobal et al., 2013) and there exist micro-
biota-derived tryptophan metabolites such as indole propionic
acid in conventionalized but not germ-free mice (Wikoff et al.,
2009). Three additional reports have shown that germ-free
mice have elevated levels of tryptophan (Clarke et al., 2013;
Diaz Heijtz et al., 2011; Desbonett et al., 2008) without explana-
tory changes in gene expression of tryptophan-utilizing enzymes
and suggest that the microbiota are participating in tryptophan
metabolism. Our discovery of tryptophan decarboxylases in
the intestinal microbiota raises the possibility that microbes
can sequester tryptophan from the diet, convert it to tryptamine,
and thereby alter the spectrum and distribution of tryptophan
metabolites that result in the host. Reducing the level of plasma
tryptophan would decrease the production of serotonin in the
brain and could represent one mechanism by which the micro-
biota influence behavior.t & Microbe 16, 495–503, October 8, 2014 ª2014 Elsevier Inc. 501
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Bacterial Growth Conditions
Clostridium sporogenes ATCC 15579 was grown in reinforced clostridiumme-
dium (BD) supplemented with MEM Vitamins (GIBCO) and incubated anaero-
bically at 37C. Ruminococcus gnavus ATCC 29149 was grown in brain heart
infusion medium (BD) supplemented with yeast extract (5 g/L) and hemin (5 g/
L) and incubated anaerobically at 37C. For the qualitative cell-based decar-
boxylation assay, cultures were grown to stationary phase in rich medium,
and the cell mass was transferred to a minimal medium (Bell, 1976) containing
5 g/L tryptophan, tyrosine, or phenylalanine. Cultures were incubated at 37C
for 24–72 hr before analysis of the culture fluid by HPLC.
Expression and Purification of CLOSPO_02083 and RUMGNA_01526
Expression constructs were transformed into E. coli BL21 (DE3) cells, grown
to saturation in LB medium (Fisher Scientific) supplemented with kanamycin
(50 mg/ml) at 37C, and diluted 1:33 into the same medium. The expression
of RUMGNA_01526 N-terminal His6 fusion proteins was induced at OD600 0.6
with 1 mM isopropyl b-D-thiogalactopyranoside, and overexpression was al-
lowed to proceed at 25C for 16–20 hr. Cells from 1 L of culture were pelleted
by centrifugation (10 min at 5200 3 g), resuspended in 40 ml of buffer A
(300 mM NaCl, 50 mM NaH2PO4, 10 mM Imidazole, pH 8.0), and lysed by
passage through a cell disruptor (EmulsiFlex C3, Avestin, Ottawa) at
10,000 pounds per square inch. Cell debris was removed by centrifugation
(20 min at 31,000 3 g) and the supernatant was incubated with 1.5 ml of
Ni-nitrilotriacetic acid resin (QIAGEN, Valencia, CA) at 4C for 1 hr. After
the unbound fraction was discarded, the resin was resuspended in 30 ml
of buffer B (300 mM NaCl, 50 mM NaH2PO4, 20 mM Imidazole, pH 8.0),
loaded onto a column, and washed with 60 ml of buffer B. Recombinant
enzyme was eluted from the column with buffer C (300 mM NaCl, 50 mM
NaH2PO4, 250 mM Imidazole, pH 8.0) and dialyzed at 4
C against 4 l of
buffer D (50 mM Tris-HCL pH 7.5, 300 mM NaCl). The protein was used
immediately, and a fresh batch was purified for each enzymatic assay. The
concentrations of purified enzyme were determined spectrophotometrically
using a Coomassie Protein Assay (Thermo Fisher). The expression of CLO-
SPO_02083 N-terminal His6 fusion proteins was performed as described
except for the following: LB medium was supplemented with 10 mM trypto-
phan and 30 mM PLP, cultures were expressed for 16–20 hr at 20C, buffers
A and D contained 30 mM PLP, and 1.0 ml of Ni-nitrilotriacetic acid resin was
used.
Qualitative Cell-Based Assay for Decarboxylase Substrate
Selectivity
Overnight cultures of E. coli BL21 (DE3) expressing pET-28a-decarboxylase
constructs were diluted (1:20) into fresh LB medium containing 50 mg/ml
kanamycin and grown for 90 min at 37C. Cells were pelleted by centrifu-
gation and resuspended in M9 minimal medium containing 5 mg/mL of
tryptophan, tyrosine, or phenylalanine and 1 mM isopropyl b-D-thiogalacto-
pyranoside. After 24 hr, 100 ml of clarified supernatant was analyzed by
HPLC.
Kinetic Characterization of CLOSPO_02083 and RUMGNA_01526
Activity with Aromatic Amino Acid Substrates
Reaction mixtures contained 50 mM sodium phosphate pH 6.5, 300 mMNaCl,
and 40 mMPLP. Reactions were initiated by the addition of enzyme and termi-
nated by quenching aliquots with 1 volume of MeOH and performed at 37C.
All substrates purchased from Sigma-Aldrich. More details provided in the
Supplemental Information.
X-ray Crystallography
Crystals of RUMGNA_01526 were grown at room temperature in hanging
drops consisting of equal volumes (1 + 1 ml) of 10 mg/ml RUMGNA_01526
and a crystallization solution composed of 0.1 M Bicine pH 8.5 and 25%
PEG 3350. Crystals of RUMGNA_01526 with (S)-a-FMT were grown at
room temperature in sitting drops consisting of equal volumes of 10 mg/mL
RUMGNA_01526 pre-mixed with 5 mM (S)-a-FMT and a crystallization solu-
tion composed of 30% ethoxyethanol, 0.1 M citrate pH 5.25, and 4% polypro-
pylene P400.502 Cell Host & Microbe 16, 495–503, October 8, 2014 ª2014 ElsevieStructure Determination and Refinement
Crystals were flash-frozen in liquid nitrogen with 10% glycerol supplemented
as a cryoprotectant. Data were collected on beamline 8.3.1 at the Advanced
Light Source (Table S1). X-ray reflections were processed using xia2. All sub-
sequent molecular replacement and structure analysis was performed using
the PHENIX software suite. For the structure of RUMGNA_01526 in its native
form, a molecular replacement search ensemble was created from the ho-
mologous models 2JIS, 3RBF, 4E1O, 3RCH, 2QMA, and 1JS3 using Phe-
nix.sculptor and Phenix.ensembler. The structure of RUMGNA_01526 in its
native form was used as a molecular replacement search model for the
(S)-a-FMT-bound structure. All visualization components were performed us-
ing COOT.
ACCESSION NUMBERS
Coordinates in the Protein Data Bank have been deposited with accession co-
des 4OBU (native RUMGNA_01526) and 4OBV (RUMGNA_01526-(S)-a-FMT
complex).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at http://dx.doi.org/10.1016/j.chom.2014.09.001.
ACKNOWLEDGMENTS
We are indebted to Justin Rettenmaier for an early computational analysis of
candidate decarboxylases from Clostridium sporogenes and to members of
theFischbachgroup for ideasandhelpful discussions. Thisworkwassupported
by a Fellowship for Science and Engineering from the David and Lucile Packard
Foundation (M.A.F.), Medical Research Program Grant from the W.M. Keck
Foundation (M.A.F.), DARPA award HR0011-12-C-0067 (M.A.F.), QB3 (J.S.F.),
and NIH grants OD007290 and GM081879 (M.A.F.) and OD009180 (J.S.F.), as
well as an HHMI Predoctoral Fellowship (P.C.) and NIH K08DK100638 (P.C.K.).
Received: May 5, 2014
Revised: July 14, 2014
Accepted: September 2, 2014
Published: September 25, 2014
REFERENCES
Anderson, G.M. (1975). Quantitation of tryptophan metabolites in rat feces by
thin-layer chromatography. J. Chromatogr. A 105, 323–328.
Bell, S.M. (1976). Treatment with gentamicin monitored by serum antibiotic
assay. Med. J. Aust. 2, 481–484.
Bhattacharjee, M.K., and Snell, E.E. (1990). Pyridoxal 50-phosphate-depen-
dent histidine decarboxylase. Mechanism of inactivation by alpha-fluorome-
thylhistidine. J. Biol. Chem. 265, 6664–6668.
Bianchetti, M.G., Minder, I., Beretta-Piccoli, C., Meier, A., and Weidmann, P.
(1982). Effects of tyramine on blood pressure and plasma catecholamines in
normal and hypertensive subjects. Klin. Wochenschr. 60, 465–470.
Bischoff, S.C., Mailer, R., Pabst, O., Weier, G., Sedlik, W., Li, Z., Chen, J.J.,
Murphy, D.L., and Gershon, M.D. (2009). Role of serotonin in intestinal inflam-
mation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitro-
benzene sulfonic acid colitis in mice. Am. J. Physiol. Gastrointest. Liver
Physiol. 296, G685–G695.
Borowsky, B., Adham, N., Jones, K.A., Raddatz, R., Artymyshyn, R., Ogozalek,
K.L., Durkin, M.M., Lakhlani, P.P., Bonini, J.A., Pathirana, S., et al. (2001).
Trace amines: identification of a family of mammalian G protein-coupled re-
ceptors. Proc. Natl. Acad. Sci. USA 98, 8966–8971.
Bravo, J.A., Forsythe, P., Chew, M.V., Escaravage, E., Savignac, H.M., Dinan,
T.G., Bienenstock, J., and Cryan, J.F. (2011). Ingestion of Lactobacillus strain
regulates emotional behavior and central GABA receptor expression in a
mouse via the vagus nerve. Proc. Natl. Acad. Sci. USA 108, 16050–16055.r Inc.
Cell Host & Microbe
Tryptamine Production in the Human MicrobiomeBrooks, J.B., Nunez-Montiel, O.L., Basta, M.T., and Hierholzer, J.C. (1984).
Studies of stools from pseudomembranous colitis, rotaviral, and other diar-
rheal syndromes by frequency-pulsed electron capture gas-liquid chromatog-
raphy. J. Clin. Microbiol. 20, 549–560.
Burkhard, P., Dominici, P., Borri-Voltattorni, C., Jansonius, J.N., and
Malashkevich, V.N. (2001). Structural insight into Parkinson’s disease treat-
ment from drug-inhibited DOPA decarboxylase. Nat. Struct. Biol. 8, 963–967.
Chander, H., Batish, V.K., Babu, S., and Singh, R.S. (1989). Factors affecting
amine production by a selected strain of Lactobacillus bulgaricus. J. Food
Sci. 54, 940–942.
Clarke, G., Grenham, S., Scully, P., Fitzgerald, P., Moloney, R.D., Shanahan,
F., Dinan, T.G., and Cryan, J.F. (2013). The microbiome-gut-brain axis during
early life regulates the hippocampal serotonergic system in a sex-dependent
manner. Mol. Psychiatry 18, 666–673.
Desbonnet, L., Garrett, L., Clarke, G., Bienenstock, J., and Dinan, T.G. (2008).
The probiotic Bifidobacteria infantis: An assessment of potential antidepres-
sant properties in the rat. J. Psychiatr. Res. 43, 164–174.
Diaz Heijtz, R., Wang, S., Anuar, F., Qian, Y., Bjo¨rkholm, B., Samuelsson, A.,
Hibberd, M.L., Forssberg, H., and Pettersson, S. (2011). Normal gutmicrobiota
modulates brain development and behavior. Proc. Natl. Acad. Sci. USA 108,
3047–3052.
Ebeid, A.M., Smith, A., Escourrou, J., Murray, P., and Fischer, J.E. (1978).
Increased immunoreactive vasoactive intestinal peptide in the cerebro-spinal
fluid (CSF) of dogs and monkeys in hepatic failure. J. Surg. Res. 25, 538–541.
Facchini, P.J., Huber-Allanach, K.L., and Tari, L.W. (2000). Plant aromatic
L-amino acid decarboxylases: evolution, biochemistry, regulation, and meta-
bolic engineering applications. Phytochemistry 54, 121–138.
Fenalti, G., Law, R.H., Buckle, A.M., Langendorf, C., Tuck, K., Rosado, C.J.,
Faux, N.G., Mahmood, K., Hampe, C.S., Banga, J.P., et al. (2007). GABA pro-
duction by glutamic acid decarboxylase is regulated by a dynamic catalytic
loop. Nat. Struct. Mol. Biol. 14, 280–286.
Fontanilla, D., Johannessen, M., Hajipour, A.R., Cozzi, N.V., Jackson, M.B.,
and Ruoho, A.E. (2009). The hallucinogen N,N-dimethyltryptamine (DMT) is
an endogenous sigma-1 receptor regulator. Science 323, 934–937.
Gallagher, T., Rozwarski, D.A., Ernst, S.R., and Hackert, M.L. (1993). Refined
structure of the pyruvoyl-dependent histidine decarboxylase from
Lactobacillus 30a. J. Mol. Biol. 230, 516–528.
Gershon,M.D., and Tack, J. (2007). The serotonin signaling system: from basic
understanding to drug development for functional GI disorders.
Gastroenterology 132, 397–414.
Giardina, G., Montioli, R., Gianni, S., Cellini, B., Paiardini, A., Voltattorni, C.B.,
and Cutruzzola`, F. (2011). Open conformation of human DOPA decarboxylase
reveals themechanism of PLP addition to Group II decarboxylases. Proc. Natl.
Acad. Sci. USA 108, 20514–20519.
Hayashi, H., Tanase, S., and Snell, E.E. (1986). Pyridoxal 50-phosphate-depen-
dent histidine decarboxylase. Inactivation by alpha-fluoromethylhistidine and
comparative sequences at the inhibitor- and coenzyme-binding sites.
J. Biol. Chem. 261, 11003–11009.
Hsiao, E.Y., McBride, S.W., Hsien, S., Sharon, G., Hyde, E.R., McCue, T.,
Codelli, J.A., Chow, J., Reisman, S.E., Petrosino, J.F., et al. (2013).
Microbiota modulate behavioral and physiological abnormalities associated
with neurodevelopmental disorders. Cell 155, 1451–1463.
Ishihara, A., Nakao, T., Mashimo, Y., Murai, M., Ichimaru, N., Tanaka, C.,
Nakajima, H., Wakasa, K., and Miyagawa, H. (2011). Probing the role of tryp-
tophan-derived secondary metabolism in defense responses against Bipolaris
oryzae infection in rice leaves by a suicide substrate of tryptophan decarbox-
ylase. Phytochemistry 72, 7–13.
Jeffery, I.B., O’Toole, P.W., O¨hman, L., Claesson, M.J., Deane, J., Quigley,
E.M., and Simre´n, M. (2012). An irritable bowel syndrome subtype defined
by species-specific alterations in faecal microbiota. Gut 61, 997–1006.Cell HosJohn, R.A. (1995). Pyridoxal phosphate-dependent enzymes. Biochim.
Biophys. Acta 1248, 81–96.
Komori, H., Nitta, Y., Ueno, H., and Higuchi, Y. (2012). Structural study reveals
that Ser-354 determines substrate specificity on human histidine decarboxy-
lase. J. Biol. Chem. 287, 29175–29183.
Lang, G., Kalvelage, T., Peters, A., Wiese, J., and Imhoff, J.F. (2008). Linear
and cyclic peptides from the entomopathogenic bacteriumXenorhabdus nem-
atophilus. J. Nat. Prod. 71, 1074–1077.
Li, J., Chen, G., and Webster, J.M. (1997). Nematophin, a novel antimicrobial
substance produced by Xenorhabdus nematophilus (Enterobactereaceae).
Can. J. Microbiol. 43, 770–773.
Linden, D.R., Chen, J.X., Gershon, M.D., Sharkey, K.A., and Mawe, G.M.
(2003). Serotonin availability is increased in mucosa of guinea pigs with
TNBS-induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 285,
G207–G216.
Linden, D.R., Foley, K.F., McQuoid, C., Simpson, J., Sharkey, K.A., andMawe,
G.M. (2005). Serotonin transporter function and expression are reduced in
mice with TNBS-induced colitis. Neurogastroenterol. Motil. 17, 565–574.
Lundgren, O. (1998). 5-Hydroxytryptamine, enterotoxins, and intestinal fluid
secretion. Gastroenterology 115, 1009–1012.
Mawe, G.M., Coates, M.D., and Moses, P.L. (2006). Review article: intestinal
serotonin signalling in irritable bowel syndrome. Aliment. Pharmacol. Ther.
23, 1067–1076.
Marcobal, A., Kashyap, P.C., Nelson, T.A., Aronov, P.A., Donia, M.S.,
Spormann, A., Fischbach, M.A., and Sonnenburg, J.L. (2013). A metabolomic
view of how the human gut microbiota impacts the host metabolome using hu-
manized and gnotobiotic mice. ISME J. 7, 1933–1943.
Mayer, E.A. (2011). Gut feelings: the emerging biology of gut-brain communi-
cation. Nat. Rev. Neurosci. 12, 453–466.
Ormsbee, H.S., 3rd, and Fondacaro, J.D. (1985). Action of serotonin on the
gastrointestinal tract. Proc. Soc. Exp. Biol. Med. 178, 333–338.
Proschak, A., Schultz, K., Herrmann, J., Dowling, A.J., Brachmann, A.O.,
ffrench-Constant, R., Mu¨ller, R., and Bode, H.B. (2011). Cytotoxic fatty acid
amides from Xenorhabdus. ChemBioChem 12, 2011–2015.
Schneider, G., Ka¨ck, H., and Lindqvist, Y. (2000). The manifold of vitamin B6
dependent enzymes. Structure 8, R1–R6.
Sudo, N., Chida, Y., Aiba, Y., Sonoda, J., Oyama, N., Yu, X.N., Kubo, C., and
Koga, Y. (2004). Postnatal microbial colonization programs the hypothalamic-
pituitary-adrenal system for stress response in mice. J. Physiol. 558, 263–275.
Takaki, M., Mawe, G.M., Barasch, J.M., Gershon, M.D., and Gershon, M.D.
(1985). Physiological responses of guinea-pig myenteric neurons secondary
to the release of endogenous serotonin by tryptamine. Neuroscience 16,
223–240.
Turvill, J.L., Connor, P., and Farthing, M.J. (2000). The inhibition of cholera
toxin-induced 5-HT release by the 5-HT(3) receptor antagonist, granisetron,
in the rat. Br. J. Pharmacol. 130, 1031–1036.
van Poelje, P.D., and Snell, E.E. (1990). Pyruvoyl-dependent enzymes. Annu.
Rev. Biochem. 59, 29–59.
Wikoff, W.R., Anfora, A.T., Liu, J., Schultz, P.G., Lesley, S.A., Peters, E.C., and
Siuzdak, G. (2009). Metabolomics analysis reveals large effects of gut micro-
flora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA 106,
3698–3703.
Yuwen, L., Zhang, F.L., Chen, Q.H., Lin, S.J., Zhao, Y.L., and Li, Z.Y. (2013).
The role of aromatic L-amino acid decarboxylase in bacillamide C biosynthesis
by Bacillus atrophaeus C89. Sci. Rep. 3, 1753.
Zucchi, R., Chiellini, G., Scanlan, T.S., and Grandy, D.K. (2006). Trace amine-
associated receptors and their ligands. Br. J. Pharmacol. 149, 967–978.t & Microbe 16, 495–503, October 8, 2014 ª2014 Elsevier Inc. 503
